Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

Blood

Volumn 119, Issue 6, 2012, Pages 1570-1580

  Srinivasan, Mathangi ^a   Flynn, Ryan ^a   Price, Andrew ^a   Ranger, Ann ^b   Browning, Jeffrey L ^b   Taylor, Patricia A ^a   Ritz, Jerome ^c   Antin, Joseph H ^c   Murphy, William J ^d   Luznik, Leo ^e   Shlomchik, Mark J ^f   Panoskaltsis Mortari, Angela ^a   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BIOGEN   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; B LYMPHOCYTE ANTIBODY; CYCLOPHOSPHAMIDE; HYBRID PROTEIN; IMMUNOGLOBULIN; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN BETA RECEPTOR IMMUNOGLOBULIN FUSION PROTEIN; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BRONCHIOLITIS OBLITERANS; CD4+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; EXPERIMENTAL MODEL; GERMINAL CENTER; IMMUNOGLOBULIN DEPOSITION; IMMUNOSUPPRESSIVE TREATMENT; LIVER FIBROSIS; LUNG FIBROSIS; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WHOLE BODY RADIATION;

EID: 84856908923     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-364414     Document Type: Article

References (43)

1. Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol. 2006;13(6):426-435. (Pubitemid 44607443)
2. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
3. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 suppl):S146-S151.
4. Baird K, Cooke K, Schultz KR. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am. 2010;57(1):297-322.
5. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica. 2008;93(11):1702-1711.
6. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood. 2008;111(6):3276-3285.
7. Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107-6114. (Pubitemid 350075069)
8. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113(16):3865-3874.
9. She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(4):386-397. (Pubitemid 46421893)
10. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+T and B cells in transplants induce chronic graftversus- host disease with autoimmune manifestations. Blood. 2006;107(7):2993-3001.
11. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168(6):3088-3098. (Pubitemid 34211692)
12. Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant. 2008;14(4):365-378.
13. Panoskaltsis-Mortari A, Tram KV, Price AP, Wendt CH, Blazar BR. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med. 2007;176(7):713-723. (Pubitemid 47503080)
14. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9(10):657-666. (Pubitemid 38351785)
15. Al-Githmi I, Batawil N, Shigemura N, et al. Bronchiolitis obliterans following lung transplantation. Eur J Cardiothorac Surg. 2006;30(6):846-851. (Pubitemid 44755355)
16. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 suppl):S106-S114.
17. Dudek AZ, Mahaseth H. Hematopoietic stem cell transplant-related airflow obstruction. Curr Opin Oncol. 2006;18(2):115-119. (Pubitemid 43740429)
18. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5(7):564-576. (Pubitemid 43971191)
19. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9(8):505-511. (Pubitemid 38351794)
20. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-762. (Pubitemid 44061381)
21. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004;104(8):2603-2606. (Pubitemid 39331867)
22. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973-2978. (Pubitemid 40446295)
23. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2009;15(9):1005-1013.
24. Browning JL. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev. 2008;223:202-220. (Pubitemid 351986178)
25. O'Neill SK, Shlomchik MJ, Glant TT, Cao Y, Doodes PD, Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol. 2005;174(6):3781-3788. (Pubitemid 40354091)
26. Blazar BR, Taylor PA, McElmurry R, et al. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer. Blood. 1998;92(10):3949-3959. (Pubitemid 28525222)
27. Chung B, Barbara-Burnham L, Barsky L, Weinberg K. Radiosensitivity of thymic interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood. 2001;98(5):1601-1606.
28. Baumgarth N, Jager GC, Herman OC, Herzenberg LA. CD4+ T cells derived from B cell-deficient mice inhibit the establishment of peripheral B cell pools. Proc Natl Acad Sci U S A. 2000;97(9):4766-4771. (Pubitemid 30238632)
29. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189(10):1639-1648.
30. Ziegler TR, Panoskaltsus-Mortari A, Gu LH, et al. Regulation of glutathione redox status in lung and liver by conditioning regimens and keratinocyte growth factor in murine allogeneic bone marrow transplantation. Transplantation. 2001;72(8):1354-1362. (Pubitemid 33015758)
31. Crawford SW, Clark JG. Bronchiolitis associated with bone marrow transplantation. Clin Chest Med. 1993;14(4):741-749. (Pubitemid 23358013)
32. Imanguli MM, Atkinson JC, Mitchell SA, et al. Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. Biol Blood Marrow Transplant. 2010;16(10):1362-1369.
33. Nagler RM, Nagler A. The molecular basis of salivary gland involvement in graft-vs.-host disease. J Dent Res. 2004;83(2):98-103. (Pubitemid 41713790)
34. Levy S, Nagler A, Okon S, Marmary Y. Parotid salivary gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model. Bone Marrow Transplant. 2000;25(10):1073-1078. (Pubitemid 30303597)
35. Novobrantseva TI, Majeau GR, Amatucci A, et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005;115(11):3072-3082. (Pubitemid 41567572)
36. Anderson SM, Hannum LG, Shlomchik MJ. Memory B cell survival and function in the absence of secreted antibody and immune complexes on follicular dendritic cells. J Immunol. 2006;176(8):4515-4519.
37. Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110(1):237-241. (Pubitemid 47026840)
38. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2):817-826. (Pubitemid 40094277)
39. Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005; 174(7):4389-4399. (Pubitemid 40396022)
40. Kuzmina Z, Greinix HT, Weigl R, et al. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. Blood. 2011;117(7):2265-2274.
41. Gatto D, Brink R. The germinal center reaction. J Allergy Clin Immunol. 2010;126(5):898-907.
42. Gommerman JL, Browning JL. Lymphotoxin/LIGHT, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol. 2003;3(8):642-655. (Pubitemid 37328667)
43. Doherty TA, Soroosh P, Khorram N, et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat Med. 2011;17(5):596-603.